JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

132.94 0.12

Overview

Share price change

24h

Current

Min

129

Max

134.58

Key metrics

By Trading Economics

Income

11M

-48M

Sales

29M

150M

Profit margin

-31.973

Employees

846

EBITDA

20M

-37M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.77% upside

Dividends

By Dow Jones

Next Earnings

3 Nov 2025

Market Stats

By TradingEconomics

Market Cap

1.4B

6.7B

Previous open

132.82

Previous close

132.94

News Sentiment

By Acuity

7%

93%

5 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Axsome Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Oct 2025, 23:28 UTC

Hot Stocks

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 Oct 2025, 23:07 UTC

Earnings

Prudential PLC 3Q New Business Profit Up 13%

30 Oct 2025, 00:00 UTC

Earnings

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 Oct 2025, 00:00 UTC

Earnings

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 Oct 2025, 00:00 UTC

Earnings

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 Oct 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 Oct 2025, 23:40 UTC

Earnings

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 Oct 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 Oct 2025, 23:25 UTC

Earnings

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 Oct 2025, 22:51 UTC

Earnings

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 Oct 2025, 22:45 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 Oct 2025, 22:41 UTC

Earnings

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 Oct 2025, 22:41 UTC

Earnings

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 Oct 2025, 22:09 UTC

Earnings

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 Oct 2025, 22:08 UTC

Market Talk
Earnings

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 Oct 2025, 21:58 UTC

Earnings

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 Oct 2025, 21:58 UTC

Earnings

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 Oct 2025, 21:57 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 Oct 2025, 21:54 UTC

Earnings

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 Oct 2025, 21:46 UTC

Earnings

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 Oct 2025, 21:43 UTC

Earnings

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 Oct 2025, 21:43 UTC

Earnings

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 Oct 2025, 21:42 UTC

Earnings

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 Oct 2025, 21:42 UTC

Earnings

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 Oct 2025, 21:41 UTC

Earnings

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 Oct 2025, 21:41 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 Oct 2025, 21:41 UTC

Earnings

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 Oct 2025, 21:41 UTC

Earnings

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 Oct 2025, 21:40 UTC

Earnings

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 Oct 2025, 21:39 UTC

Earnings

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

29.77% upside

12 Months Forecast

Average 173.25 USD  29.77%

High 200 USD

Low 148 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

107.24 / 112.29Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

5 / 373 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat